文献速递细菌感染、耐药与抗菌药物病毒性肝炎艾滋病与性传播感染

感染性疾病药物成本:品牌药、仿制药及为何应关注

The Costs of Drugs in Infectious Diseases: Branded, Generics, and Why We Should Care.
PubMed 文献 · J Infect Dis · 2020-01-01

本文讨论美国药品价格上涨对感染性疾病治疗的影响,指出专利保护与市场独占导致品牌药价格高昂,且部分无专利独占的仿制药(如阿苯达唑、乙胺嘧啶、青霉素)在缺乏竞争时也无法保证持久低价。作者提出通过教育、成本意识指南制定、政府监管和市场激励来控制药价、扩大可及性。

要点

  • 品牌药因专利独占可定价过高,如Sovaldi、Zyvox、Truvada。
  • 仿制药在缺乏竞争时也可能无法保持低价,如阿苯达唑、乙胺嘧啶、青霉素。
  • 可通过教育、指南制定、监管与市场激励协作控制药价。

核心结论

  • 美国药品价格上涨部分源于品牌药高价,专利保护与市场独占加剧不公平结局并减少可及性。
  • 仿制药在缺乏制造商竞争时也不保证持久低价。
  • 通过教育、成本意识指南制定、政府监管和市场激励,医疗提供者可协作控制药价并扩大可及性。

主要发现

  • 品牌药制造商对独占药物定价过高障碍少,如Sovaldi、Zyvox和Truvada。
  • 阿苯达唑、乙胺嘧啶和青霉素表明无专利独占的仿制药在缺乏竞争时不一定持久低价。

临床怎么用

  • 医疗提供者应通过教育和意识提升关注药品成本。
  • 制定指南时考虑成本意识。
  • 支持政府监管和市场层面激励以控制药价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While health care providers have largely turned a blind eye, the cost of health care in the US has been skyrocketing, in part as a result of rising drug prices. Patent protections and market exclusivity, while serving to incentivize targeted new drug development, have exacerbated inequitable outcomes and reduced access, sometimes fueling national epidemics. Branded drug manufacturers face few barriers to exorbitant pricing of drugs with exclusivity-as in the cases of Sovaldi, Zyvox, and Truvada. Furthermore, albendazole, pyrimethamine, and penicillin demonstrate that generic medications without patent exclusivity are not guaranteed to have durably low costs, especially where manufacturer competition is lacking. There is a way forward: through education and awareness, cost-conscious guideline development, government regulation, and market-level incentives, health care providers can collaborate to contain drug prices, curbing expenditures overall while expanding health care access to patients.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Costantini S, Walensky RP. The Costs of Drugs in Infectious Diseases: Branded, Generics, and Why We Should Care. J Infect Dis. 2020. PMID: 30887033. doi:10.1093/infdis/jiz066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。